Plain-English translation of NCT06445322 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a prescreening study designed to identify people who may be good candidates for a larger clinical trial testing a new treatment called ACDN-01. Researchers will perform genetic testing and vision assessments to determine if you have the specific genetic form of Stargardt disease (caused by mutations in the ABCA4 gene) and whether this medication might be right for you. This study helps researchers find the right patients before enrolling them in the full treatment trial.
Stargardt disease is a rare inherited eye condition that causes vision loss, and currently there are limited treatment options. This prescreening step exists to efficiently identify patients who have the specific genetic cause of the disease, so researchers can test whether this new treatment might help slow or stop the vision loss in people who truly have this form.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will come in for at least one visit where the research team will conduct genetic testing and vision assessments. These tests are designed purely to determine whether you meet the eligibility requirements for the larger ACDN-01 clinical trial. The entire prescreening process is relatively brief and non-invasive—it's a straightforward evaluation to see if you're a good candidate for the next phase of research.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States